Cyterix Pharmaceuticals
Oncology prodrugs targeting tumor-specific enzymes for cancer therapy
About Cyterix Pharmaceuticals
Cyterix Pharmaceuticals was a biotechnology company focused on developing novel, small molecule cancer therapeutics through a specialized prodrug approach. Founded in April 2010 by Professor Steven A. Everett, the late Dr. John Curd, and Professor Paul Ortiz de Montellano, the company was built on a foundation of deep expertise in prodrug development and cytochrome P450 biochemistry. Professor Everett, who served as President and CEO, invented the company's core OncoCYP™-targeted prodrug discovery approach. This technology was developed at the University of Dundee in Scotland with support from Cancer Research UK and was exclusively licensed to Cyterix.
The company's business model centered on its proprietary technology platform, which was designed to create anticancer prodrugs activated selectively by extra-hepatic cytochrome P450 enzymes. These enzymes, referred to as OncoCYP™ enzymes, are significantly over-expressed in a wide range of solid and hematologic cancers but are not present in normal tissues. This tumor-specific activation aimed to overcome the dose-limiting toxicities of conventional chemotherapy by delivering potent cytotoxic agents directly to cancer cells, thereby improving safety and efficacy. Cyterix's strategy was to advance its lead compounds, which used approved drugs as 'warheads', through IND-enabling studies and into Phase 1 clinical trials to establish proof-of-concept.
In June 2011, Cyterix announced a $9.2 million Series A financing round from The Column Group and SV Life Sciences to fund these developments. The company raised a total of approximately $8.8 million over two rounds. Despite its promising technology and initial funding, Cyterix Pharmaceuticals is no longer in business.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Cyterix Pharmaceuticals in the San Francisco ecosystem
The Cyterix Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
SV Health Investors
The Column Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyterix Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyterix Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


